Opicapone

Opicapone
Clinical data
Trade namesOngentys, Ontilyv
Other namesBIA 9-1067
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B2[1]
  • Not recommended
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[2]
  • US: ℞-only[3]
  • EU: Rx-only[4][5]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability~20%
Protein binding99.9%
MetabolismMainly sulfation, also reduction, glucuronidation, methylation
Elimination half-life0.7 to 3.2 hours
Duration of action>24 hours
ExcretionFeces (67%), urine (13%)
Identifiers
  • 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H10Cl2N4O6
Molar mass413.17 g·mol−1
3D model (JSmol)
  • Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1
  • InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
  • Key:ASOADIZOVZTJSR-UHFFFAOYSA-N

Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease.[3][6][4][5] Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.[3]

The most common side effects are dyskinesia (difficulty controlling movement), constipation, increased blood creatine kinase, hypotension/syncope, and decreased weight.[3][6]

Opicapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination.[4] It enhances the effects of levodopa, a precursor of the neurotransmitter dopamine that can be taken by mouth.[4] Opicapone blocks an enzyme that breaks down levodopa in the body called catechol-O-methyltransferase (COMT).[3][4] It is peripherally selective and does not inhibit COMT in the brain.[7] As a result of its COMT inhibition, levodopa remains active for longer.[4] This helps to improve the symptoms of Parkinson's disease, such as stiffness and slowness of movement.[4]

In June 2016, it was authorised for use in the European Union.[4][8][9] It was authorised for use in the United States in April 2020.[10][6][9]

Medical uses

In the EU, opicapone is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adults with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.[4]

In the US, opicapone is indicated as adjunctive treatment to levodopa/carbidopa in people with Parkinson's disease (PD) experiencing "off" episodes.[3][6]

The COMT inhibitor opicapone is used as an additive to a combination of levodopa and a DOPA decarboxylase inhibitor to treat patients with Parkinson's disease experiencing end-of-dose motor fluctuations, if they cannot be stabilised with this drug combination.[11]

Contraindications

This drug is contraindicated in people with cancers that secrete catecholamines (for example epinephrine), such as pheochromocytoma or paraganglioma, because as a COMT inhibitor it blocks catecholamine degradation. Other contraindications are a history of neuroleptic malignant syndrome (NMS) or non-traumatic rhabdomyolysis, and combination with monoamine oxidase inhibitors that are not used as antiparkinsonians, because of possible drug interactions.[11]

NMS and associated rhabdomyolysis have been rarely observed under the older COMT inhibitors tolcapone and entacapone. This typically occurs shortly after the beginning of a COMT inhibitor add-on therapy when the levodopa dose has been reduced, or after discontinuation of a COMT inhibitor.[12]

Opicapone is contraindicated in people with concomitant use of non-selective monoamine oxidase (MAO) inhibitors or people with pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.[3][4]

Side effects

People taking opicapone very commonly (18%) experience dyskinesia. Other common side effects (in 1 to 10% of patients) include dizziness, strange dreams, hallucinations, constipation, dry mouth, orthostatic hypotension (low blood pressure), and muscle spasms.[11] Apart from spasms, these side effects are also known from tolcapone and entacapone.[12]

As with entacapone, no relevant liver toxicity has been found in studies. This is in contrast to the first COMT inhibitor tolcapone, which could cause – in some cases lethal – liver insufficiency.[12][13]

Overdose

No specific antidote is known.[11]

Interactions

Monoamine oxidase inhibitors (MAO inhibitors) are another class of drugs blocking catecholamine degradation. Therefore, their combination with opicapone can result in increased catecholamine concentrations in the body and corresponding adverse effects. Combining the antiparkinson MAO inhibitors selegiline or rasagiline with opicapone is considered safe. Potentially, there are also interactions with drugs being metabolised by COMT (for example isoprenaline, epinephrine, dopamine, or dobutamine), tricyclic antidepressants and antidepressants of the norepinephrine reuptake inhibitor type. Possible pharmacokinetic interactions are with substrates of the liver enzyme CYP2C8, such as repaglinide, and the transporter protein SLCO1B1, such as simvastatin.[11]

Pharmacology

Mechanism of action

Opicapone blocks the enzyme catechol-O-methyltransferase (COMT) effectively (>90% at therapeutic doses), selectively and reversibly, and only outside the central nervous system. It dissociates slowly from COMT, resulting in a duration of action longer than 24 hours despite its short blood plasma half-life.[11][13] As COMT and DOPA decarboxylase are the main enzymes for degrading levodopa, blocking the two effectively increases its concentrations in the bloodstream. More levodopa reaches the brain, where it is activated to dopamine.[14]

Pharmacokinetics

Opicapone and some of its metabolites: the main inactive metabolite opicapone sulfate (BIA 9–1103), the active reduced derivative (BIA 9–1079), and the inactive glucuronide (BIA 9–1106).[15]

The substance is quickly absorbed from the gut, but only to about 20% of the applied dose. Highest blood plasma concentrations are reached after 1 to 2.5 hours. When in the bloodstream, it is almost completely (99.9%) bound to plasma proteins, but apparently to different binding sites than warfarin, digoxin and other drugs with high plasma protein affinity. It is mainly metabolised to the sulfate, which accounts for 67% of the circulating drug after a single dose, and a methylated derivative, which accounts for 21%. Minor metabolites are a reduced derivative (<10%) and a glucuronide. All of these metabolites are inactive except the reduced derivative. Opicapone is eliminated with a terminal half-life of 0.7 to 3.2 hours. It is mainly excreted via the faeces (67%), and in form of the glucuronide also via the kidney (13%). The sulfate has a much longer half-life of 94 to 122 hours.[11][13][15]

Opicapone sulfate is transported by SLCO1B1; the possibility that it blocks this transporter has not been excluded. Opicapone itself and the sulfate are also transported by a number of other proteins, but given the low concentrations of the free substances in the blood plasma, this is very unlikely to give rise to drug interactions. Opicapone is a weak inhibitor of the liver enzymes CYP1A2, CYP2B6, CYP2C8, and CYP2C9. The only CYP interaction found in studies that is somewhat likely to be relevant is that with repaglinide, which is metabolised by CYP2C8. The metabolism of warfarin, a CYP2C9 substrate, is not measurably affected.[11]

Opicapone does not cross the blood–brain barrier and hence is a peripherally selective drug.[7]

History

Opicapone was authorised for medical use in the European Union in June 2016.[4][8][9]

In February 2017, its developer Bial sold exclusive marketing rights for the United States and Canada to Neurocrine Biosciences for an initial payment of US$30 million.[16]

Opicapone was authorised for medical use in the United States in April 2020.[10][6][9]

Opicapone was approved based on evidence from two clinical trials (Trial 1/ NCT01568073, and Trial 2/NCT01227655) of 522 participants with Parkinson's disease (PD) whose symptoms were not well controlled while receiving their regular PD treatment.[6] Trial 1 was conducted at 104 sites in 19 European countries, and Trial 2 was conducted at 69 sites in Argentina, Australia, Belgium, Chile, Czech Republic, Estonia, India, Israel, South Korea, Russia, South Africa and UK.[6]

There were two 12-week trials conducted in Parkinson's disease (PD) participants with inadequate control of their Parkinson's symptom ("off" time) while receiving carbidopa/levodopa PD medications.[6] Participants were randomly selected to receive either opicapone or a placebo capsule once a day.[6] Neither the participants nor the health care providers knew which treatment was being given until the trial was completed.[6]

In all of the trials, the participants kept daily diaries of the number of hours of "off" time for the three days before the evaluation visit.[6] The benefit was evaluated by measuring the change from baseline in total daily "off" time in opicapone- and placebo-receiving participants.[6]

Society and culture

On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ontilyv, intended for the treatment of Parkinson's disease.[17] The applicant for this medicinal product is Bial Portela & Companhia S.A.[17] Opicapone was approved for medical use in the European Union in February 2022.[4][18]

References

  1. ^ "Australian Public Assessment Report for Opicapone" (PDF). Therapeutic Goods Administration. February 2021. Archived from the original (PDF) on 13 June 2021.
  2. ^ "Ongentys 50 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 18 July 2019. Archived from the original on 4 June 2020. Retrieved 28 April 2020.
  3. ^ a b c d e f g "Ongentys- opicapone capsule". DailyMed. 24 April 2020. Archived from the original on 25 October 2021. Retrieved 30 September 2020.
  4. ^ a b c d e f g h i j k l "Ongentys EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 9 May 2020. Retrieved 28 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ a b "Ontilyv EPAR". European Medicines Agency. 14 December 2021. Archived from the original on 7 August 2022. Retrieved 25 August 2022.
  6. ^ a b c d e f g h i j k l "Drug Trials Snapshots: Ongentys". U.S. Food and Drug Administration (FDA). 24 April 2020. Archived from the original on 21 September 2020. Retrieved 13 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  7. ^ a b Fabbri M, Rosa MM, Ferreira JJ (October 2016). "Clinical pharmacology review of opicapone for the treatment of Parkinson's disease". Neurodegener Dis Manag. 6 (5): 349–62. doi:10.2217/nmt-2016-0022. PMID 27599671. Opicapone (OPC) is a novel, long-acting, peripherally selective, once daily, third-generation catechol-O-methyl transferase inhibitor.
  8. ^ a b "Neurocrine Nabs BIAL's PD Therapy Opicapone for North America". Genetic Engineering & Biotechnology News. 10 February 2017. Archived from the original on 2 July 2018. Retrieved 8 April 2017.
  9. ^ a b c d "Neurocrine Biosciences Announces FDA Approval of Once-Daily Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes". Neurocrine Biosciences (Press release). 27 April 2020. Archived from the original on 28 April 2020. Retrieved 28 April 2020.
  10. ^ a b "Ongentys: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 28 April 2020. Retrieved 28 April 2020.
  11. ^ a b c d e f g h "Ongentys: EPAR – Product Information" (PDF). European Medicines Agency (EMA). 28 January 2020. Archived (PDF) from the original on 7 October 2018. Retrieved 26 August 2022.
  12. ^ a b c Haberfeld H, ed. (2017). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Comtan, Tasmar.
  13. ^ a b c Annus Á, Vécsei L (2017). "Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy". Drug Design, Development and Therapy. 11: 143–151. doi:10.2147/DDDT.S104227. PMC 5234693. PMID 28123288.
  14. ^ Mutschler E, Schäfer-Korting M (2001). Arzneimittelwirkungen (in German) (8th ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 315. ISBN 3-8047-1763-2.
  15. ^ a b Rocha JF, Almeida L, Falcão A, Palma PN, Loureiro AI, Pinto R, et al. (November 2013). "Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects". British Journal of Clinical Pharmacology. 76 (5): 763–75. doi:10.1111/bcp.12081. PMC 3853535. PMID 23336248.
  16. ^ "Brief: Neurocrine and Bial reports exclusive North American licensing agreement for opicapone". Reuters. 9 February 2017. Archived from the original on 8 August 2019. Retrieved 1 July 2017.
  17. ^ a b "Ontilyv: Pending EC decision". European Medicines Agency. 16 December 2021. Archived from the original on 17 December 2021. Retrieved 18 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  18. ^ "Ontilyv Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.

Further reading

Read other articles:

Danau EdwardFoto citra satelit NASA Danau Edward dan Danau George, yang menunjukkan Saluran Kazinga di antara keduanyaKoordinat0°20′S 29°36′E / 0.333°S 29.600°E / -0.333; 29.600Koordinat: 0°20′S 29°36′E / 0.333°S 29.600°E / -0.333; 29.600Aliran masuk utamaNyamugasaniIshashaRutshuruRwindiNtungweLubiliaAliran keluar utamaSungai SemlikiWilayah tangkapan air12.096 km²Terletak di negaraRepublik Demokratik KongoUgandaPanjang maksimal7...

 

 

本條目存在以下問題,請協助改善本條目或在討論頁針對議題發表看法。 此條目需要补充更多来源。 (2018年3月17日)请协助補充多方面可靠来源以改善这篇条目,无法查证的内容可能會因為异议提出而被移除。致使用者:请搜索一下条目的标题(来源搜索:羅生門 (電影) — 网页、新闻、书籍、学术、图像),以检查网络上是否存在该主题的更多可靠来源(判定指引)。 �...

 

 

Phase of the Cold War World map of alliances in 1970 (legend) The 1975 Apollo-Soyuz space rendez-vous, one of the attempts at cooperation between the US and the USSR during the détente The Cold War (1962–1979) refers to the phase within the Cold War that spanned the period between the aftermath of the Cuban Missile Crisis in late October 1962, through the détente period beginning in 1969, to the end of détente in the late 1970s. The United States maintained its Cold War engagement with t...

Sydney Town Hall Sydney Town Hall adalah sebuah markah tanah berupa bangunan batu pasir yang terletak di jantung Sydney. Berdiri di seberang Queen Victoria Building dan di samping St Andrew's Cathedral. Berada di atas stasiun Town Hall dan antara jalan bioskop di George Street dan Central Business District, tangga Town Hall adalah tempat bertemu paling populer. Sejarah dan penjelasan Town Hall dibangun tahun 1880-an -- terletak di tanah bekas pemakaman tua -- dari batu pasir Sydney dengan gay...

 

 

Questa voce o sezione contiene informazioni riguardanti una tornata elettorale attesa o annunciata o i cui dati non sono ancora ufficiali. Il contenuto potrebbe cambiare radicalmente non appena i risultati saranno proclamati ufficialmente dagli uffici elettorali competenti. Per favore, non aggiungere speculazioni alla voce. Elezioni europee del 2024 Area  Unione europea Stato  Italia Legislatura X Eletti 76 Europarlamentari Seggi per gruppo politico ECR 0 / 76 S&D 0 / 76 NI 0 /...

 

 

2016年美國總統選舉 ← 2012 2016年11月8日 2020 → 538個選舉人團席位獲勝需270票民意調查投票率55.7%[1][2] ▲ 0.8 %   获提名人 唐納·川普 希拉莉·克林頓 政党 共和黨 民主党 家鄉州 紐約州 紐約州 竞选搭档 迈克·彭斯 蒂姆·凱恩 选举人票 304[3][4][註 1] 227[5] 胜出州/省 30 + 緬-2 20 + DC 民選得票 62,984,828[6] 65,853,514[6]...

1900年美國總統選舉 ← 1896 1900年11月6日 1904 → 447張選舉人票獲勝需224張選舉人票投票率73.2%[1] ▼ 6.1 %   获提名人 威廉·麥金利 威廉·詹寧斯·布賴恩 政党 共和黨 民主党 家鄉州 俄亥俄州 內布拉斯加州 竞选搭档 西奧多·羅斯福 阿德萊·史蒂文森一世 选举人票 292 155 胜出州/省 28 17 民選得票 7,228,864 6,370,932 得票率 51.6% 45.5% 總統選舉結果地圖,紅色代表�...

 

 

English footballer Ricky Ravenhill Ravenhill with the victory parade that followed Bradford City's victory in the 2013 Football League Two play-off finalPersonal informationFull name Richard John Ravenhill[1]Date of birth (1981-01-16) 16 January 1981 (age 43)Place of birth Doncaster, EnglandHeight 5 ft 8 in (1.73 m)Position(s) MidfielderTeam informationCurrent team Mickleover(Assistant Manager)Youth career1998–2000 BarnsleySenior career*Years Team Apps (Gls)2000�...

 

 

هذه المقالة يتيمة إذ تصل إليها مقالات أخرى قليلة جدًا. فضلًا، ساعد بإضافة وصلة إليها في مقالات متعلقة بها. (ديسمبر 2023)Learn how and when to remove this message جمعية تعليم العلوم المقر الرئيسي جامعة هيرتفوردشاير  تاريخ التأسيس 1963  الموقع الرسمي الموقع الرسمي  تعديل مصدري - تعديل   ج�...

This article's lead section may be too short to adequately summarize the key points. Please consider expanding the lead to provide an accessible overview of all important aspects of the article. (October 2023) Barnes 1867-68 football seasonBarnes1867-68 seasonCaptainRobert WillisSecretaryRobert GrahamRulesLaws of the Game (1867)← 1866-671868-69 → This was the sixth season of Barnes Football Club. Barnes v C.C.C. 19 October 1867 Barnes 1-0 C.C.C. Barnes Nettleship Note: ...

 

 

Swiss alpine skier Beat FeuzFeuz in 2012Personal informationBorn (1987-02-11) 11 February 1987 (age 37)Schangnau, Bern,SwitzerlandOccupationAlpine skierHeight1.72 m (5 ft 8 in)Skiing careerDisciplinesDownhill, super-G, combinedClubSchangnauWorld Cup debut10 December 2006 (age 19)Websitebeat-feuz.chOlympicsTeams3 – (2014, 2018, 2022)Medals3 (1 gold)World ChampionshipsTeams5 – (2011, 2015–21)Medals3 (1 gold)World CupSeasons14 – (2007, 2010–2012,  ...

 

 

Road in the Philippines Expressway 1Route informationPart of AH26 Maintained by NLEX Corporation and SMC TPLEX CorporationMajor junctionsMajor intersections N213 (Magalang–Concepcion Road) in Concepcion, Tarlac N2 (MacArthur Highway) in Mabalacat E1 (North Luzon Expressway) in Mabalacat N301 (Roman Superhighway) in Dinalupihan, Bataan E1 (Subic–Clark–Tarlac Expressway) in Mabalacat N3 (Jose Abad Santos Avenue) in San Fernando AH 26 (N1) (Maharlika Highway) in Guiguinto N247 (Plaridel By...

Dialect of Assamese This article is about the modern dialect group of Assamese. For the historical language spoken in Kamarupa, see Kamarupi Prakrit. Kamrupi dialectsPronunciation/ˈkæmruːpi/[1]Native toIndiaRegionKamrup regionEthnicityKamrupi peopleLanguage familyIndo-European Indo-IranianIndo-AryanEasternBengali-AssameseAssameseKamrupi dialectsDialectsBarpetia dialect Nalbariya dialect Palasbaria dialectWriting system Assamese alphabet Language codesISO 639-3–GlottologNone ...

 

 

Subregion in Asia This article is about the geographical subregion of Asia. For the physiographical region of Eurasia, see Indian subcontinent.Not to be confused with Southern Asia (UN geoscheme). South AsiaArea5,222,321 km2 (2,016,349 sq mi)Population2.04 billion (2024)[1]Population density362.3/km2 (938/sq mi)GDP (PPP)$18.05 trillion (2024)[2]GDP (nominal)$5.04 trillion (2024)[3]GDP per capita$2,650 (nominal) (2024)$9,470 (PPP) (202...

 

 

The topic of this article may not meet Wikipedia's notability guideline for biographies. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.Find sources: William Gordon Weld – news · newspapers · books · scholar · JSTOR (...

American basketball player (born 1996) Emmanuel MudiayMudiay with the New York Knicks in 2018No. 32 – Piratas de QuebradillasPositionPoint guardLeagueBSNPersonal informationBorn (1996-03-05) March 5, 1996 (age 28)Kinshasa, Zaire (now DR Congo)NationalityCongolese / AmericanListed height6 ft 3 in (1.91 m)Listed weight200 lb (91 kg)Career informationHigh school Grace Prep (Arlington, Texas) Prime Prep (Dallas, Texas) NBA draft2015: 1st round, 7th overall ...

 

 

زهير الذوادي معلومات شخصية الميلاد 1 يناير 1988 (العمر 36 سنة)القيروان، تونس الطول 1.80 م (5 قدم 11 بوصة) مركز اللعب وسط الجنسية  تونس معلومات النادي النادي الحالي النادي الإفريقي الرقم 15 مسيرة الشباب سنوات فريق النادي الإفريقي سنوات فريق م. (هـ.) 2006–2012 النادي الإفريقي 108...

 

 

Chief executive of Major League Baseball This article is about the Major League Baseball commissioner. For the Nippon Professional Baseball commissioner, see Commissioner of Baseball (NPB). Commissioner of BaseballIncumbentRob Manfredsince January 25, 2015PrecursorNational Baseball CommissionInaugural holderKenesaw Mountain LandisFormation1920WebsiteOfficial website The Commissioner of Baseball is the chief executive officer of Major League Baseball (MLB) and the associated Minor League ...

Football clubFC Samgurali TskaltuboFull nameს.კ. სამგურალი წყალტუბოFounded1945; 79 years ago (1945)Ground26 May StadiumCapacity3,500OwnerMikheil IashviliCoachMikheil AshvetiaLeagueErovnuli Liga2023Erovnuli Liga, 5thWebsiteClub website Home colours Away colours Third colours FC Samgurali (Georgian: საფეხბურთო კლუბი სამგურალი) is a Georgian association football club from Tskaltubo, which take...

 

 

Alexander Crum BrownLahir(1838-03-26)26 Maret 1838Meninggal28 Oktober 1922(1922-10-28) (umur 84)KebangsaanBritania RayaAlmamaterUniversitas EdinburghKarier ilmiahMahasiswa ternamaAcharya Prafulla Chandra Ray Alexander Crum Brown FRSE FRS (26 Maret 1838 – 28 Oktober 1922) adalah seorang kimiawan organik Skotlandia. Alexander Crum Brown Road di kompleks King's Buildings, Edinburgh mengambil nama dari beliau. Bacaan tambahan Testimonials in favour of Alexander Crum Brown (M...